Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Reduced Dose IPV Hexavalent Vaccine vs HEXASIIL® in Infants
NCT06413121Phase 3Completed
- Sponsor
- Serum Institute of India
- Start
- May 2024
- Primary completion
- Mar 2025
- Modality
- Prophylactic Vaccines
- Countries
- 2
01
Overview
A Phase 3 trial of Hexavalent Vaccine in diphtheria, Tetanus, pertussis, hepatitis B (HBV), Haemophilus influenzae type b infection (Hib), sponsored by Serum Institute of India. Started May 2024; status: completed.
02
Drugs
Hexavalent Vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT06413121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413121.